Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 6581-6590 Newer>

The Motley Fool March 30, 2005 Jeff Hwang	Many Ways to Play the Market Pick an investment strategy, find the right company at the right price, and be ready to pounce.
The Motley Fool March 30, 2005 Travers & Smith	Stock Madness 2005: Protein Design Labs vs. Plum Creek Timber This biotech isn't as risky as you might think. But is it as solid as a tree company? Find out in "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness.
The Motley Fool March 30, 2005 Slaughter & Smith	Stock Madness 2005: UPS vs. Coca-Cola Brown fizzy liquid does battle with brown delivery trucks in "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness.
The Motley Fool March 30, 2005 Charly Travers	Stock Madness 2005: Celgene vs. Netflix Biotech battles entertainment in this Round 3 matchup of "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness.
The Motley Fool March 30, 2005 Nathan Parmelee	Stride Rite Springs Ahead Shoe designer steps up to the platform and begins large share repurchases.
The Motley Fool March 30, 2005 Stephen D. Simpson	Trucker Hits a Pothole Trucking company U.S. Xpress is the latest to announce soft conditions in the first quarter.
The Motley Fool March 30, 2005 Tom Taulli	How Does Google Gauge Success? Measuring Web traffic is becoming a strategic business, as Google's latest acquisition shows. This is good news for the Web analytics providers, as the deals should logically push values higher.
The Motley Fool March 30, 2005 Alyce Lomax	Scholastic's Impending Potter Mania A record-breaking print run heralds the approach of this summer's new Harry Potter book. From an investment point of view, the publisher hasn't had too much else going on between Potter books.
The Motley Fool March 30, 2005 Stephen D. Simpson	Clinical Trials Cost Biotechs More The failure of edifoligide means little to Bristol-Myers, but a great deal to Corgentech. In the grand scheme of things, there's not much new here -- the large, well-stocked pharmaceutical goes on its way, and the biotech stock gets pummeled.
The Motley Fool March 30, 2005 Rich Duprey	Controlling Interest in Net Access Supreme Court hears the case of opening cable Internet access to competition and regulation. The decision will have important consequences that may become irrelevant if satellites, power lines or other means of transmission become more prevalent. Investors, take note.
<Older 6581-6590 Newer> Return to current articles.